N
TRVI icon

Nuveen’s Trevi Therapeutics TRVI Stock Holding History

Nuveen’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
188,182
+4,853
+3% +$54.3K ﹤0.01% 2236
2025
Q4 		$2.3M Hold
183,329
– – ﹤0.01% 2231
2025
Q3 		$1.68M Buy
183,329
+13,870
+8% +$104K ﹤0.01% 2369
2025
Q2 		$927K Sell
169,459
-104,161
-38% -$648K ﹤0.01% 2639
2025
Q1 		$1.72M Buy
273,620
+177,270
+184% +$846K ﹤0.01% 2392
2024
Q4 		$397K Hold
96,350
– – ﹤0.01% 3057
2024
Q3 		$322K Hold
96,350
– – ﹤0.01% 3130
2024
Q2 		$287K Buy
96,350
+21,501
+29% +$59.7K ﹤0.01% 3161
2024
Q1 		$258K Hold
74,849
– – ﹤0.01% 3128
2023
Q4 		$100K Buy
74,849
+7,914
+12% +$12K ﹤0.01% 3286
2023
Q3 		$146K Hold
66,935
– – ﹤0.01% 3084
2023
Q2 		$160K Buy
+66,935
New +$169K ﹤0.01% 3122

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return